Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on May 7, 2019. The filing serves to announce company highlights and financial results for the first quarter ended March 31, 2019. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main body text. It directs readers to the attached press release (Exhibit 99.1) for the announcement of company highlights and financial results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information disclosed under Item 2.02, including the press release, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it shall not be incorporated by reference into any registration statement except as expressly set forth. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the May 7, 2019 press release), as they are absent from the 8-K body.
- Confirm the company name is Trovagene, Inc. (Ticker: TROV), noting the discrepancy with the metadata field "Cardiff Oncology, Inc."
- Review the press release for any updates on clinical trial progress or operational milestones mentioned as "company highlights."
- Check subsequent filings for any restatements or updates to the Q1 2019 results.